736 related articles for article (PubMed ID: 32021227)
1. Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan.
Sokos GG; Raina A
Vasc Health Risk Manag; 2020; 16():41-51. PubMed ID: 32021227
[TBL] [Abstract][Full Text] [Related]
2. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
3. Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF).
Okumura N; Jhund PS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ;
Circulation; 2016 Jun; 133(23):2254-62. PubMed ID: 27143684
[TBL] [Abstract][Full Text] [Related]
4. Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives.
Yandrapalli S; Andries G; Biswas M; Khera S
Vasc Health Risk Manag; 2017; 13():369-382. PubMed ID: 29042791
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
Hsiao FC; Wang CL; Chang PC; Lu YY; Huang CY; Chu PH
J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):152-157. PubMed ID: 31514513
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial.
DeVore AD; Mi X; Thomas L; Sharma PP; Albert NM; Butler J; Hernandez AF; Patterson JH; Spertus JA; Williams FB; Duffy CI; McCague K; Fonarow GC
J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29895587
[TBL] [Abstract][Full Text] [Related]
7. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
Mohanty AF; Levitan EB; Dodson JA; Vardeny O; King JB; LaFleur J; He T; Patterson OV; Alba PR; Russo PA; Choi ME; Bress AP
Circ Heart Fail; 2019 Nov; 12(11):e005691. PubMed ID: 31718321
[TBL] [Abstract][Full Text] [Related]
9. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.
Jhund PS; McMurray JJ
Heart; 2016 Sep; 102(17):1342-7. PubMed ID: 27207980
[TBL] [Abstract][Full Text] [Related]
10. Sacubitril/valsartan: from a large clinical trial to clinical practice.
Sciatti E; Senni M; Lombardi CM; Gori M; Metra M
J Cardiovasc Med (Hagerstown); 2018 Sep; 19(9):473-479. PubMed ID: 29917003
[TBL] [Abstract][Full Text] [Related]
11. The eligible population of the PARADIGM-HF trial in a real-world outpatient clinic and its cardiovascular risk between 2005 and 2016.
Chen X; Schaufelberger M; Fu M
J Cardiovasc Med (Hagerstown); 2020 Jan; 21(1):6-12. PubMed ID: 31789711
[TBL] [Abstract][Full Text] [Related]
12. "Real World" Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry.
Simpson J; Benson L; Jhund PS; Dahlström U; McMurray JJV; Lund LH
Cardiovasc Drugs Ther; 2019 Jun; 33(3):315-322. PubMed ID: 30903545
[TBL] [Abstract][Full Text] [Related]
13. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
Okumura N; Jhund PS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ;
Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27618854
[TBL] [Abstract][Full Text] [Related]
14. Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction.
Fudim M; Sayeed S; Xu H; Matsouaka RA; Heidenreich PA; Velazquez EJ; Yancy CW; Fonarow GC; Hernandez AF; DeVore AD
Circ Heart Fail; 2020 Apr; 13(4):e006645. PubMed ID: 32248695
[TBL] [Abstract][Full Text] [Related]
15. Sacubitril/Valsartan in Real-Life Practice: Experience in Patients with Advanced Heart Failure and Systematic Review.
Moliner-Abós C; Rivas-Lasarte M; Pamies Besora J; Fluvià-Brugues P; Solé-González E; Mirabet S; López López L; Brossa V; Pirla MJ; Mesado N; Álvarez-García J; Roig E
Cardiovasc Drugs Ther; 2019 Jun; 33(3):307-314. PubMed ID: 30820802
[TBL] [Abstract][Full Text] [Related]
16. Sacubitril/Valsartan (LCZ696) in Heart Failure.
Khder Y; Shi V; McMurray JJV; Lefkowitz MP
Handb Exp Pharmacol; 2017; 243():133-165. PubMed ID: 28004291
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
[TBL] [Abstract][Full Text] [Related]
18. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
Desai AS; Vardeny O; Claggett B; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Zile MR; Lefkowitz M; Shi V; Solomon SD
JAMA Cardiol; 2017 Jan; 2(1):79-85. PubMed ID: 27842179
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its long-term side effects.
Krittanawong C; Kitai T
Cardiovasc Ther; 2017 Aug; 35(4):. PubMed ID: 28489317
[TBL] [Abstract][Full Text] [Related]
20. Switching from ramipril to sacubitril/valsartan favorably alters electrocardiographic indices of ventricular repolarization in heart failure with reduced ejection fraction.
Okutucu S; Sabanoglu C; Yetis Sayin B; Aksoy H; Bursa N; Oto A
Acta Cardiol; 2020 Feb; 75(1):20-25. PubMed ID: 30513267
[No Abstract] [Full Text] [Related]
[Next] [New Search]
